Clinical Trial Update: The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating mesylate apatinib combined with docetaxel and S-1 as first-line therapy for metastatic gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• S-1 (tegafur/gimeracil/oteracil)
• mesylate apatinib (apatinib)

Snippet

Sponsor: Zhou Fuxiang | Conditions: Metastatic Gastric Cancer | Phase 2 | Status: UNKNOWN